The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Single-cell RNA sequencing of tumor and immune cells in patients with plasma cell premalignancy
Romanos Sklavenitis-Pistofidis, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the results of a large single-cell RNA sequencing study of tumor and immune cells in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and overt myeloma. The study analyzed over 6 million cells from 365 individuals and identified immune biomarkers of disease progression, including increased cytotoxic T-cells, clonal T-cell expansion, and pro-inflammatory changes in myeloid cells. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
